Back to search

Article

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer

2021-04-12

Abstract excerpt

Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay, however almost all patients will eventually transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC generally develop symptomatic metastatic disease (mCRPC) and incur mortality several years later. Pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b89f3a95-7164-5934-8ba0-77c9ed63a4fa
DOI
10.20944/preprints202104.0287.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate CancerDOI 10.20944/preprints202104.0287.v1
Select a neighboring publication to make it the new centre.